Drugs / AZD0284
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03310320 | Nov 2017 → Apr 2018 | psoriasis | AstraZeneca | Terminated | No outcome recorded |
| Phase 1 | NCT03029741 | Feb → Mar 2017 | psoriasis | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02976831 | Dec 2016 → May 2017 | psoriasis | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD0284 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02976831 ↗ |
| Route | Oral | “4.0 mg AZD0284 (oral solution)” NCT02976831 ↗ |